<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, oral bisphosphonate use has increased markedly in the United States and elsewhere </plain></SENT>
<SENT sid="1" pm="."><plain>Little is known about <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks associated with these drugs </plain></SENT>
<SENT sid="2" pm="."><plain>A few studies have observed associations between bisphosphonates and the risk of breast, colorectal and <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and the risk of other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> have not been investigated </plain></SENT>
<SENT sid="4" pm="."><plain>In our study, we examined the risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and site specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in individuals taking bisphosphonates </plain></SENT>
<SENT sid="5" pm="."><plain>Data were extracted from the UK General Practice Research Database to compare site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence in a cohort of oral bisphosphonate users and a control cohort </plain></SENT>
<SENT sid="6" pm="."><plain>Hazard ratios (HRs) were calculated using Cox regression modeling </plain></SENT>
<SENT sid="7" pm="."><plain>The bisphosphonate and control cohort contained 41,826 participants (mean age 70, 81% female) </plain></SENT>
<SENT sid="8" pm="."><plain>Overall, the bisphosphonate cohort compared with the control cohort had a reduced risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> after any bisphosphonate usage [HR=0.87, 95% confidence interval (CI) 0.82, 0.92] </plain></SENT>
<SENT sid="9" pm="."><plain>In the bisphosphonate cohort, compared with the control cohort, there was no evidence of a difference in the risk of lung (HR=1.03, 95% CI 0.88, 1.20) or <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (HR=0.86, 95% CI 0.67, 1.09) but breast (HR=0.71, 95% CI 0.62, 0.81) and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (HR=0.74, 95% CI, 0.60-0.91) were both reduced </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings indicate that bisphosphonates do not appear to increase <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="11" pm="."><plain>Although reductions in breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> incidence were observed in bisphosphonate users it is unclear, particularly for <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, to what extent confounding by low bone density may explain the association </plain></SENT>
</text></document>